Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 529-536

  Nherera, L ^a,b   Calvert, N W ^a   Demott, K ^a   Humphries, S E ^c   Neil, H A W ^d   Minhas, R ^e   Thorogood, M ^f  

^a ROYAL COLLEGE OF GENERAL PRACTITIONERS   (United Kingdom)

^b National Collaborating Centre for Women's and Children's Health   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BRITISH MEDICAL ASSOCIATION   (United Kingdom)

^f UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cost effectiveness; Familial hypercholesterolaemia; Markov modelling; QALYs; Statins

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COST BENEFIT ANALYSIS; DRUG COST; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; HEART FAILURE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STROKE; THEORETICAL MODEL; THEORETICAL STUDY; UNSTABLE ANGINA PECTORIS;

ADULT; AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MODELS, THEORETICAL; RISK FACTORS;

EID: 74549114679     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903494934     Document Type: Article

References (28)

1. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-420
2. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk (letter). J Med Genet 2006;43:943-949
3. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-112
4. DeMott K, Nherera L, Shaw EJ, et al. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008
5. Metcalfe S. Technology Assessment Report No. 2. Costs and benefits of simvastatin 40 mg vs fluvastatin 80 mg for patients with familial hyperlipidae-mia. Technology Assessment Reports. Wellington, NZ: PHARMAC, 1997
6. Ara R, Tumur I, Pandor A, et al. Ezetimibe for the treatment of hypercholester-olaemia: a systematic review and economic evaluation. Health Technol Assess 2008;12:1-212
7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435
8. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
10. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z trial. JAMA 2004;292:1307-1316
11. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hyperch-olesterolaemia (ASAP): a prospective randomized, double-blind trial. Lancet 2001;357:577-581
12. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology Appraisal. London: National Institute for Health and Clinical Excellence 2006. Available from: http://www.nice.org.uk/Guidance/TA94 [Last accessed 30 October 2009].
13. Government Actuary's Department. Interim Life Tables: Government Actuary's Department, 2006 Available from: http://www.gad.gov.uk/Demography- Data/Life-Tables/Interim-life-tables.asp. [Last accessed 30 October 2009]
14. Department of Health. NHS Costing Manual 2008/9. Reference Costs 2008. Dept of Health 2008 Available from http://www.dh.gov.uk/PolicyAndGuidance/ OrganisationPolicy/FinanceAndPlanning/NHSCosting Manual/fs/en. [Last accessed 30 October 2009]
15. NHS Business Services Authority. Prescription Pricing Division. NHS Electronic Drug Tariff, 2008
16. Prescott-Clarke P, Primatesta P. Health Survey for England '96: The Stationery Office, 1997
17. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278
18. Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21:1123-1130
19. Packham C, Gray D, Silcocks P, et al. Identifying the risk of death following hospital discharge in patients admitted with a suspected acute myocardial infarction in whom the diagnosis is not confirmed. Eur Heart J 2000;21:213-219
20. Versmissen J, Oosterveer DM, Yazdanapanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J 2008; 337:a2423, doi:10.1136/bmj.a2423
21. Neil A, Humphries SE. Statins and familial hypercholesterolaemia. BMJ 2009;338:a3041, doi: 10.1136/bmj.a3041
22. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003;326:1423-1429
23. Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007;115:2398-2409
24. National Institute for Health and Clinical Excellence. Hypertension: Management of hypertension in adults in primary care. CG34. London: National Institute for Health and Clinical Excellence 2006. Available from http://guidance.nice.org.uk/CG34.[Last accessed 30 October 2009]
25. Karnon J, Akehurst R, Brennan A, et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin 2005;21:101-112
26. Mason JM, Freemantle N, Gibson JM, et al. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care 2005;28:40-46
27. Davies A, Hutton J, O'Donnell J, et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006;13:196-202
28. Yock CA, Boothroyd DB, Owens DK, et al. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med 2003;115:382-389